Endometriosis prophylaxis and treatment with the newly developed xenogenic immunomodulator RESAN in an animal model

Szymanowski K, Krzysztof Szymanowski, Karolina Chmaj-Wierzchowska, Chmaj-Wierzchowska K, Andrey Yantczenko, Yantczenko A, Joanna Niepsuj-Biniaś, Niepsuj-Biniaś J, Ewa Florek, Opala T, Tomasz Opala, Murawski M, Marek Murawski
European journal of obstetrics, gynecology, and reproductive biology · 2008 · vol. 142(2) , pp. 145–148 · doi:10.1016/j.ejogrb.2008.09.017 · PMID:19059697 · W2073687468
article OA: closed CC0 ⤵ 10 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This study investigated the efficacy of the novel xenogenic immunomodulator RESAN for both preventing and treating endometriosis in an animal model.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveThe objective was to assess the effectiveness of the newly developed immunomodulator RESAN in the prophylaxis and treatment of endometriosis induced in rats.Study designThe study was performed on 58 Wistar rats. Twelve weeks before endometriosis induction, the RESAN vaccine was administered to 24 rats (100 mg i.m. and 100 mg s.c.). Endometriosis induction was performed in 48 rats, which were divided into two groups: group I, the prophylaxis group, consisting of 24 previously vaccinated rats; and group II, the treatment group, comprising the other 24 rats, which had not been vaccinated. The graft (4 mm x 4 mm) of endometrium was attached to the parietal peritoneum. A sham operation was performed in 10 rats (group III). After 3 months, a second laparotomy was performed in all animals, and endometriotic foci were excised when present. RESAN was administered to the group II animals. After an additional 3 months, a third laparotomy was performed in all animals of the three groups.ResultsPositive, histologically confirmed endometriosis was found in 4.3% of the animals in group I and in 69.6% of group II rats (p<0.0001). Macroscopic assessment revealed endometriosis in 21.7% and 91.3% of animals in groups I and II, respectively (p<0.0001). At final laparotomy, 3 months after excision of the previously suspected foci, no signs of endometriosis were found according to both macroscopic assessment and histological examination. During the second laparotomy intraperitoneal adhesions were present in 13.0% of the animals in group I and in 61.0% of those in group II. No adhesions were present in group III. At the final laparotomy, the adhesions were present in only three of the animals in group II (p<0.0009).ConclusionsRESAN seems to be effective in both the prophylaxis and treatment of endometriosis, as well as in the prophylaxis of adhesions. Histological confirmation of endometriosis should be mandatory.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Cancer Vaccines Endometriosis Immunologic Factors Animals Antigens, Heterophile Antigens, Heterophile Cancer Vaccines Disease Models, Animal Endometriosis Endometriosis Female Immunologic Factors Rats Rats, Wistar Tissue Adhesions Tissue Adhesions

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (23)

Cited by (10)

Source provenance

europepmc
last seen: 2026-07-26T06:08:39.051465+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:14:18.065553+00:00
License: CC0 · commercial use OK